← All trials
NCT05087381
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Jan 30, 2022
- First posted
- Oct 21, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 1800
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chulalongkorn UniversityLead sponsor
- Chulalongkorn UniversityOverall official - principal investigator
- Chulalongkorn UniversityReponsible party - principal investigator
- Chulalongkorn UniversityCollaborator
- Mae Fah Luang University HospitalCollaborator
- Mahidol UniversityCollaborator
- Government of ThailandCollaborator
- Government of ThailandStudy director
- University of QueenslandCollaborator
- University of QueenslandStudy chair
- Rajavithi Hospital, BangkokCollaborator
- Rajavithi Hospital, BangkokStudy chair
- Mahidol UniversityCollaborator
- University of Western AustraliaCollaborator
- Washington University in St. LouisCollaborator
- Yamagata Prefectural Central HospitalCollaborator
- Yamagata Prefectural Central HospitalStudy chair
- Chulalongkorn UniversityOfficial
- Government of ThailandOfficial
- Rajavithi Hospital, BangkokOfficial
- Chulalongkorn UniversitySponsor investigator
- Yamagata Prefectural Central HospitalOfficial
- University of QueenslandOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.